Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity.It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively
Mechanism of Revaprazan Hydrochloride
Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea,but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively
Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively
Revaprazan Hydrochloride is the hydrochloride salt form of a lipophilic, weak base with potassium-competitive acid blocking (P-CAB) activity. It is a drug that reduces gastric acid secretion which is used for the treatment of gastritis. It acts as an acid pump antagonist (potassium-competitive acid blocker). Revaprazan is approved for use in Korea, but is not approved in Europe or the United States. Revaprazan concentrates highly in the gastric parietal cell canaliculus and on entering this acidic environment is instantly protonated and binds competitively
……………………information not available & the product goes to under development, or trialing. Further information
References
About the author